GOSS Gossamer Bio Inc Future Profit
The net profit forecast visualizes the potential of Gossamer Bio, Inc. (GOSS) within the cardiovascular pathology niche, where therapy exclusivity will ensure high drug pricing. captures the magnitude of this parameter. Growth is based on the implementation of inhaled seralutinib for the treatment of pulmonary hypertension. Additionally, Gossamer Bio, Inc. (GOSS) is implementing AI algorithms and automating biomaterial processing in its laboratories.
Analytical breakdowns for Gossamer Bio, Inc.
- share price and consensus valuation forecast:
- market capitalization data:
- book capitalization information:
- company total debt and liquidity indicators:
Debt to Equity Gossamer Bio, Inc.|GOSS - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Gossamer Bio Corp.|GOSS - Company Aggregate Debts|Debt to Book Capitalization Ratio Gossamer Bio Corp.|GOSS - Company Long-Term Indebtedness|Company Short-Term Debts Gossamer Bio|Quick Ratio gossamerbio.com
- earnings and valuation multiples information:
GOSS - Annual Net Income|Expected Profit Gossamer Bio, Inc.|GOSS - Market Cap to Earnings|Future Price to Earnings Gossamer Bio Corp.|GOSS - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Gossamer Bio Corp.|GOSS - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Gossamer Bio|GOSS - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months gossamerbio.com|GOSS - Net earnings per share growth this year|Earnings growth forecast for next year Gossamer Bio, Inc.
- revenue and sales details:
Basic company analysis:GOSS, Gossamer Corp
The efficiency of complex biomaterial logistics during immunological drug trials at Gossamer Bio, Inc. (GOSS) directly determines research accuracy and the future commercial value of the therapy. Analyzing the prospective profit chart, an investor can observe the discounted earnings per share in a daily cross-section, allowing for the timely detection of systemic business degradation or the confirmation of capital stability via an upward trend in the metric.
Competing companies
ARGX (argenx.com) - Projected Future Earnings|Projected Future Earnings BioNTech Group|Future Profit ABVX (ABIVAX)|ADMA (ADMA Bio) - Expected Net Income|Projected Future Earnings PTGX (protagonist-inc.com)|Company Profit Forecast immunovant.com (IMVT)|KNSA - Expected Profit|Grifols SA (GRFS) - Future Profit|Adaptive Biotechnologies Inc. (ADPT) - Expected Profit|Future Profit Celldex Therapeutics|Future Profit AUPH|Projected Future Earnings biocryst.com|Expected Profit Vera Pharma (VERA)|Dianthus Therapeutics, Inc. - Net Profit Forecast|Projected Future Earnings PHVS (pharvaris.com)|AbCellera Bio (ABCL) - Expected Net Profit|TRML: Future Profit|Forward Earnings PGEN|PHAR: Projected Future Earnings|Expected Net Profit Nektar Therapeutics Inc (NKTR)|Future Profit UPB|Net Profit Forecast ZBIO (Zenas Biopharma, Inc.)|Future Profit IMNM (Immunome Bio)|Expected Profit KALV (KalVista Pharmaceuticals)|Projected Future Earnings SEPN (Septerna Pharma)|Company Profit Forecast Pieris Pharma (PVLA)|Savara Inc - Projected Future Earnings|Expected Net Income RIGL (Rigel Corp)|anaptysbio.com (ANAB) - Expected Profit|Astria Therapeutics, Inc. - Expected Net Income|ENGN (enGene) - Projected Future Earnings|Expected Net Profit RAPT Therapeutics Inc. RAPT|Future Profit JBIO (Aerovate Therapeutics, Inc.)|Future Net Profit ACRS|Projected Future Earnings KYTX (Kyverna Therapeutics)|Company Profit Forecast Tiziana Life Sciences (TLSA)|Cabaletta Bio - Projected Future Earnings|Company Profit Forecast Ventyx Biosciences, Inc. VTYX|Theratechnologies Inc (THTX) - Expected Profit|Forward Earnings AVTX (Avalo Therapeutics Inc.)|ELDN (Eledon Pharmaceuticals, Inc) - Projected Future Earnings|Projected Future Earnings agenusbio.com|Projected Future Earnings CLYM|Future Net Profit ZURA|Projected Future Earnings ATYR (aTyr Pharmaceuticals)|Expected Net Income ADAG|ImageneBio Inc - Projected Future Earnings|STTK (shattucklabs.com) - Net Profit Forecast|EQ: Projected Future Earnings|Connect Biopharma Holdings (CNTB) - Projected Future Earnings|IMUX (immunic-therapeutics.com) - Projected Future Earnings|ATRA (Atara Biotherapeutics) - Future Net Profit|Projected Future Earnings IFRX|Projected Future Earnings X4 Pharmaceuticals, Inc (XFOR)|Projected Future Earnings ACET (Adicet Bio Inc.)|CELU (Celularity Corp) - Forward Earnings|INmune Bio Corp - Projected Future Earnings|BRNS - Projected Future Earnings|Kezar Life Sciences, Inc (KZR) - Expected Profit|SABS (sabbiotherapeutics.com) - Expected Profit|Expected Profit Akari Therapeutics|Expected Profit ENLV|Expected Profit Q32 Bio Inc (QTTB)|GOVX (GeoVax Corp) - Expected Net Income|Projected Future Earnings EDSA (Edesa Biotech Corp)|IBIO: Net Profit Forecast|Carisma Therapeutics Inc. - Projected Future Earnings|XTLB: Expected Profit|BOLT: Projected Future Earnings|Future Profit HCW Biologics, Inc.|Expected Profit aptevotherapeutics.com|Net Profit Forecast AIM (AIM ImmunoTech Inc.)|Future Profit ADTX (Aditxt)|GRI (GRI Bio) - Expected Net Income|Projected Future Earnings XRTX (XORTX Therapeutics Inc)|Company Profit Forecast Vyome Therapeutics (HIND)|REVB - Expected Profit|INDP - Projected Future Earnings|SCNI: Projected Future Earnings|Net Profit Forecast CALI|AFMD (Affimed Therapeutics) - Projected Future Earnings|Projected Future Earnings allakos.com|Future Profit HOOK (hookipapharma.com)|Future Profit IGM Bio IGMS|Projected Future Earnings ITOS (iTeos Pharma)|OCEA - Future Profit|TC BioPharm (Holdings) PLC - Projected Future Earnings|Third Harmonic Bio, Inc - Future Net Profit
